Literature DB >> 10982183

Linkage and LOH studies in 19 cylindromatosis families show no evidence of genetic heterogeneity and refine the CYLD locus on chromosome 16q12-q13.

M Takahashi1, E Rapley, P J Biggs, S R Lakhani, D Cooke, J Hansen, E Blair, B Hofmann, R Siebert, G Turner, D G Evans, C Schrander-Stumpel, F A Beemer, W A van Vloten, M H Breuning, A van den Ouweland, D Halley, B Delpech, M Cleveland, I Leigh, P Chapman, J Burn, D Hohl, J P Görög, S Seal, J Mangion.   

Abstract

Familial cylindromatosis is an autosomal dominant predisposition to multiple neoplasms of the skin appendages. The susceptibility gene has previously been mapped to chromosome 16q12-q13 and has features of a recessive oncogene/tumour suppressor gene. We have now evaluated 19 families with this disease by a combination of genetic linkage analysis and loss of heterozygosity in cylindromas from affected individuals. All 15 informative families show linkage to this locus, providing no evidence for genetic heterogeneity. Recombinant mapping has placed the gene in an interval of approximately 1 Mb. There is no evidence, between families, of haplotype sharing that might be indicative of common founder mutations.

Entities:  

Mesh:

Year:  2000        PMID: 10982183     DOI: 10.1007/s004399900227

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  12 in total

Review 1.  Controlling hair follicle signaling pathways through polyubiquitination.

Authors:  Erik G Huntzicker; Anthony E Oro
Journal:  J Invest Dermatol       Date:  2008-05       Impact factor: 8.551

2.  Epidermal CYLD inactivation sensitizes mice to the development of sebaceous and basaloid skin tumors.

Authors:  Yingai Jane Jin; Sally Wang; Joshua Cho; M Angelica Selim; Tim Wright; George Mosialos; Jennifer Y Zhang
Journal:  JCI Insight       Date:  2016-07-21

Review 3.  Emerging role of ubiquitination in antiviral RIG-I signaling.

Authors:  Jonathan Maelfait; Rudi Beyaert
Journal:  Microbiol Mol Biol Rev       Date:  2012-03       Impact factor: 11.056

4.  CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels.

Authors:  Paula Miliani de Marval; Shazia Lutfeali; Jane Y Jin; Benjamin Leshin; M Angelica Selim; Jennifer Y Zhang
Journal:  Cancer Prev Res (Phila)       Date:  2011-04-08

5.  Defective laminin 5 processing in cylindroma cells.

Authors:  Lucy Tunggal; Juliette Ravaux; Monika Pesch; Hans Smola; Thomas Krieg; Françoise Gaill; Takako Sasaki; Rupert Timpl; Cornelia Mauch; Monique Aumailley
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

6.  The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer.

Authors:  Jennifer Y Zhang; Maria Angelica Selim
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

Review 7.  Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.

Authors:  Patrick W Blake; Jorge R Toro
Journal:  Hum Mutat       Date:  2009-07       Impact factor: 4.878

8.  Identification of a large rearrangement in CYLD as a cause of familial cylindromatosis.

Authors:  Ans M W van den Ouweland; Peter Elfferich; Roy Lamping; Raoul van de Graaf; Monique M van Veghel-Plandsoen; S M Franken; A C Houweling
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

9.  The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor.

Authors:  Alexandre Regamey; Daniel Hohl; Jia Wei Liu; Thierry Roger; Priit Kogerman; Rune Toftgard; Marcel Huber
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

10.  Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD.

Authors:  Nadine Hövelmeyer; F Thomas Wunderlich; Ramin Massoumi; Charlotte G Jakobsen; Jian Song; Marcus A Wörns; Carsten Merkwirth; Andrew Kovalenko; Monique Aumailley; Dennis Strand; Jens C Brüning; Peter R Galle; David Wallach; Reinhard Fässler; Ari Waisman
Journal:  J Exp Med       Date:  2007-10-08       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.